Summary
BAP1-related mutations are common genetic lesions of several cancers and neurodevelopmental disorders (NDDs). BAP1 is a deubiquitinase that removes the repressive mono-ubiquitination at histone H2AK119 (H2Aub1) deposited by the Polycomb Repressive Complex 1 (PRC1) by associating with several regulatory subunits to form the Polycomb Repressive Deubiquitinase (PR-DUB) complex.
BAP1 inactivating mutations represent a hallmark in Malignant Mesothelioma (MM) for which genetic models proved its oncogenic role. Mutations further extend to several other cancers, also involving other essential PR-DUB regulatory subunits. This makes PR-DUB inactivation a major oncogenic event with ~40k new diagnosis each year between EU and US for which no precision therapeutic approaches exist.
The work of my Dissect-PcG ERC project found that the major role of BAP1 is to counteract H2Aub1 diffusion across the entire chromatin. This preserves chromatin plasticity enhancing Polycomb-mediated control of transcriptional identity, which is decommissioned when BAP1 is inactivated and oncogenic H2Aub1 accumulates. We also found that diffused H2Aub1 is controlled by a specific form of PRC1 - namely PRC1.3/5 - immediately suggesting a strategy to “correct” the effects of BAP1-related mutations. Indeed, we found that specific PRC1.3/5 loss restored normal H2Aub1 levels while compromising MM cells viability, demonstrating the therapeutic potential of targeting this non-essential arm of PRC1 repressive machinery.
By building a multidisciplinary team, the T-BAP project aims to develop compounds that can target PRC1.3/5 in living cells. We propose to use PRC1.3/5 structural data to identify specific binders that can function as warheads for the development of PROTAC degraders. This will generate a new class of molecules for the development of therapeutic strategies that can aid oncological patients with BAP1-related mutations, with a further potential application in specific NDD syndromes.
BAP1 inactivating mutations represent a hallmark in Malignant Mesothelioma (MM) for which genetic models proved its oncogenic role. Mutations further extend to several other cancers, also involving other essential PR-DUB regulatory subunits. This makes PR-DUB inactivation a major oncogenic event with ~40k new diagnosis each year between EU and US for which no precision therapeutic approaches exist.
The work of my Dissect-PcG ERC project found that the major role of BAP1 is to counteract H2Aub1 diffusion across the entire chromatin. This preserves chromatin plasticity enhancing Polycomb-mediated control of transcriptional identity, which is decommissioned when BAP1 is inactivated and oncogenic H2Aub1 accumulates. We also found that diffused H2Aub1 is controlled by a specific form of PRC1 - namely PRC1.3/5 - immediately suggesting a strategy to “correct” the effects of BAP1-related mutations. Indeed, we found that specific PRC1.3/5 loss restored normal H2Aub1 levels while compromising MM cells viability, demonstrating the therapeutic potential of targeting this non-essential arm of PRC1 repressive machinery.
By building a multidisciplinary team, the T-BAP project aims to develop compounds that can target PRC1.3/5 in living cells. We propose to use PRC1.3/5 structural data to identify specific binders that can function as warheads for the development of PROTAC degraders. This will generate a new class of molecules for the development of therapeutic strategies that can aid oncological patients with BAP1-related mutations, with a further potential application in specific NDD syndromes.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101111993 |
| Start date: | 01-01-2024 |
| End date: | 30-06-2025 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
BAP1-related mutations are common genetic lesions of several cancers and neurodevelopmental disorders (NDDs). BAP1 is a deubiquitinase that removes the repressive mono-ubiquitination at histone H2AK119 (H2Aub1) deposited by the Polycomb Repressive Complex 1 (PRC1) by associating with several regulatory subunits to form the Polycomb Repressive Deubiquitinase (PR-DUB) complex.BAP1 inactivating mutations represent a hallmark in Malignant Mesothelioma (MM) for which genetic models proved its oncogenic role. Mutations further extend to several other cancers, also involving other essential PR-DUB regulatory subunits. This makes PR-DUB inactivation a major oncogenic event with ~40k new diagnosis each year between EU and US for which no precision therapeutic approaches exist.
The work of my Dissect-PcG ERC project found that the major role of BAP1 is to counteract H2Aub1 diffusion across the entire chromatin. This preserves chromatin plasticity enhancing Polycomb-mediated control of transcriptional identity, which is decommissioned when BAP1 is inactivated and oncogenic H2Aub1 accumulates. We also found that diffused H2Aub1 is controlled by a specific form of PRC1 - namely PRC1.3/5 - immediately suggesting a strategy to “correct” the effects of BAP1-related mutations. Indeed, we found that specific PRC1.3/5 loss restored normal H2Aub1 levels while compromising MM cells viability, demonstrating the therapeutic potential of targeting this non-essential arm of PRC1 repressive machinery.
By building a multidisciplinary team, the T-BAP project aims to develop compounds that can target PRC1.3/5 in living cells. We propose to use PRC1.3/5 structural data to identify specific binders that can function as warheads for the development of PROTAC degraders. This will generate a new class of molecules for the development of therapeutic strategies that can aid oncological patients with BAP1-related mutations, with a further potential application in specific NDD syndromes.
Status
SIGNEDCall topic
ERC-2022-POC2Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
